Status:
RECRUITING
Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology
Lead Sponsor:
Neolys
Collaborating Sponsors:
Centre Francois Baclesse
Centre Hospitalier Universitaire de Caen
Conditions:
Radiosensitivity
Pediatric Cancer
Eligibility:
All Genders
3-18 years
Phase:
NA
Brief Summary
Analysis of the individual radiosensitivity in pediatric oncology
Eligibility Criteria
Inclusion
- Minor patient treated for a brain tumor, Ewing tumor, malignant mesenchymal tumor, neuroblastoma, nephroblastoma, Hodgkin's lymphoma treated with radiotherapy (+/- chemotherapy) for curative purposes.
- Children or adolescents \> 3 years old and \< 18 years old
- Patient with an indication for radiotherapy as part of the primary tumor local control strategy
- Theoretical indication for radiotherapy in standard fractionation (1.8 Gy to 2.2 Gy / fraction: 5 fr/week) whatever the technique and the particle used
- Patient affiliated with a social security scheme
- Patient and/or parents or holders of parental authority having dated and signed an informed consent
- Exclusion criteria:
- Patients with contraindications to blood sampling
- Patients with contraindications to radiotherapy
- Palliative radiotherapy
- Patient with previous RT treatment in the same area (re-irradiation)
- Patient with an indication of hypofractionated RT
- Patient follow-up not possible
- Persons deprived of liberty or under guardianship (including curatorship)
Exclusion
- \-
Key Trial Info
Start Date :
December 2 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06033183
Start Date
December 2 2023
End Date
October 30 2027
Last Update
November 22 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre François Baclesse
Caen, France
2
Centre Oscar Lambret
Lille, France